Blueprint
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For
period ending 19 January
2017
GlaxoSmithKline plc
(Name
of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or
will
file annual reports under cover Form 20-F or Form 40-F
Form
20-F x Form 40-F
--
Indicate
by check mark whether the registrant by furnishing the
information
contained in this Form is also thereby furnishing the
information
to the Commission pursuant to Rule 12g3-2(b) under the
Securities
Exchange Act of 1934.
Yes
No x
Issued:
Thursday 19 January 2017, London UK - LSE Announcement
Abbas Hussain to leave GSK
GlaxoSmithKline plc
(LSE/NYSE: GSK) today announced that Abbas Hussain, President,
Global Pharmaceuticals has decided to leave the company. He has
agreed with GSK that he will leave the company later this
year.
Abbas
joined GSK in 2008 and has held roles of increasing responsibility
within the company's pharmaceutical business. He is a member of
GSK's executive team and a board member of ViiV
Healthcare.
Under
his leadership, pharmaceutical and vaccine commercial performance
in the US and European businesses has significantly improved, and
the company has delivered a series of successful new product
launches. At the last reported quarter, new pharmaceutical sales
represented 25% of total pharmaceutical sales.
He has
also built the world's leading emerging markets pharmaceuticals
business by volume, and implemented a flexible approach to pricing
across developing countries, helping GSK top the Access to Medicine
Index each time since its 2008 launch.
Abbas
successfully led the implementation of GSK's new commercial
operating model across more than 100 countries, bringing increased
transparency to GSK's interactions with healthcare
professionals.
Sir Andrew Witty, CEO, GSK commented,
"In his time at GSK Abbas has proven himself to be one of the most
talented and authentic leaders in the healthcare industry. I am
personally grateful for his tremendous energy and support as a
member of our executive team. Succession processes are challenging
for everyone involved and, unfortunately, it is rare that all of
those involved stay with the company. I wish him well in his future
and thank him for the significant contribution he has made to GSK
and the lives of many patients around the world."
-Ends-
GSK - one of
the world's leading research-based pharmaceutical and healthcare
companies - is committed to improving the quality of human life by
enabling people to do more, feel better and live longer. For
further information please visit www.gsk.com.
|
GSK enquiries:
|
|
|
|
|
UK
Media enquiries:
|
David
Mawdsley
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Simon
Steel
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Anna
Carruth
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
|
|
|
|
US
Media enquiries:
|
Sarah
Alspach
|
+1 202
715 1048
|
(Washington,
DC)
|
|
|
Sarah
Spencer
|
+1 215
751 3335
|
(Philadelphia)
|
|
|
|
|
|
|
Analyst/Investor
enquiries:
|
Sarah
Elton-Farr
|
+44 (0)
20 8047 5557
|
(London)
|
|
|
Tom
Curry
|
+ 1 215
751 5419
|
(Philadelphia)
|
|
|
Gary
Davies
|
+44 (0)
20 8047 5503
|
(London)
|
|
|
James
Dodwell
|
+44 (0)
20 8047 2406
|
(London)
|
|
|
Jeff
McLaughlin
|
+1 215
751 7002
|
(Philadelphia)
|
Inside
information
The
information contained in this announcement is inside information.
If you have any queries on this, then please contact Victoria Whyte
GSK Company Secretary (responsible for arranging the release of
this announcement) at GSK House Brentford, Middlesex, TW8 9GS on
+44 208 047 5000.
|
Cautionary statement regarding forward-looking statementsGSK
cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described under Item 3.D
'Risk factors' in the company's Annual Report on Form 20-F for
2015.
|
|
Registered in England & Wales:
No. 3888792
|
|
|
|
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS
|
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorised.
|
|
GlaxoSmithKline plc
|
|
|
(Registrant)
|
|
|
|
|
Date: January
19, 2017
|
|
|
|
|
|
|
By: VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GlaxoSmithKline plc
|